John Vandermosten

Robert Hoffman

Dick Williams

Tony Bowers

Glenn Primack

Paul Rosenbaum

- Dyadic Applied BioSolutions announced **milestone achievements** in Q3 2025, including a **$500,000 payment** anticipated in Q4 2025 from its Proliant Health & Biologicals partnership for Recombinant Human Albumin, and a **$250,000 payment** received from its Inzymes ApS partnership for non-animal dairy enzymes.  **[1213809_0001493152-25-017306_ex99-1.htm:0]** 
- The company **regained compliance** with Nasdaq's minimum market value and minimum bid price requirements in early October 2025, with the previously issued deficiency notices now closed.  **[1213809_0001493152-25-017306_form8-k.htm:2]** 
- Dyadic's President and COO, Joe Hazelton, stated the company is advancing its transition to a **commercially focused, revenue-driven company**, with commercial launches for key products targeted for late 2025 and early 2026.  **[1213809_0001493152-25-017306_ex99-1.htm:0]**

Dyadic Achieves Milestones and Regains Nasdaq Compliance

- **Dyadic Applied BioSolutions** achieved **milestone payments** in Q3 2025 from collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, as the company advances its transition to a commercially focused entity.  **[1213809_cbb5d07190524308a6f2eeef1d5aa647_0]** **[1213809_cbb5d07190524308a6f2eeef1d5aa647_1]** 
- A **$500,000** milestone payment from Proliant Health & Biologicals is anticipated in Q4 2025, with the commercial launch of Recombinant Human Albumin targeted for late 2025 and early 2026.  **[1213809_cbb5d07190524308a6f2eeef1d5aa647_0]** 
- Dyadic received a **$250,000** milestone payment from Inzymes ApS in Q3 2025, with the first enzyme's scale-up on track for a late 2025 launch.  **[1213809_cbb5d07190524308a6f2eeef1d5aa647_1]**

Dyadic Applied BioSolutions Announces Milestone Achievements and Commercial Progress

- **Dyadic Applied Bio Solutions (DYAI)** has **rebranded and restructured** over the past three years, shifting its focus to **high-growth non-therapeutic markets** (life sciences, food/nutrition, bioindustrial) using its C1 Adaptabus and Dapivis fungal expression platforms, aiming for faster and more reliable revenue generation.  **[1213809_2147199_1]** **[1213809_2147199_2]** 
- The company is at a **commercial inflection point**, transitioning from an R&D-reliant model to a **revenue-focused bioprocessing platform company**, with initial revenues from partnerships and product launches now active.  **[1213809_2147199_1]** **[1213809_2147199_3]** **[1213809_2147199_8]** 
- Key product launches and partnerships expected to drive revenue include recombinant human albumin with **Proliant Health and Biologicals** (launching 2025), **DNase I** (launching 2025), and non-animal dairy enzymes with **Enzymes** (launching late 2025).  **[1213809_2147199_3]** **[1213809_2147199_4]** **[1213809_2147199_6]** 
- Dyadic targets approximately **$25 billion in addressable market opportunities** across these segments and anticipates becoming **cash flow positive by the end of 2026**.  **[1213809_2147199_1]** **[1213809_2147199_7]** **[1213809_2147199_9]**

DYADIC INTERNATIONAL (DYAI)